| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0025-7753(17)30625-5 |
| P698 | PubMed publication ID | 28760225 |
| P2093 | author name string | Pablo Gómez-Fernández | |
| Diego Fernández-García | |||
| P2860 | cites work | Euglycemic diabetic ketoacidosis induced by SGLT2 inhibitors: possible mechanism and contributing factors | Q42616924 |
| Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes | Q46818617 | ||
| Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. | Q53084508 | ||
| Pathologic classification of diabetic nephropathy. | Q55052603 | ||
| Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Diabetic Ketoacidosis Among Patients With Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials | Q87683744 | ||
| SGLT2 Inhibitors May Predispose to Ketoacidosis | Q28081173 | ||
| Adverse effects and safety of SGLT-2 inhibitors | Q28082331 | ||
| Renal autoregulation in health and disease | Q28082365 | ||
| The renal vascular response to diabetes | Q33917570 | ||
| Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice | Q35194026 | ||
| Sodium Glucose Cotransporter 2 (SGLT2) Plays as a Physiological Glucose Sensor and Regulates Cellular Contractility in Rat Mesangial Cells | Q35964702 | ||
| Effects of sodium-glucose cotransporter-2 inhibitors on cardiovascular events, death, and major safety outcomes in adults with type 2 diabetes: a systematic review and meta-analysis. | Q35968414 | ||
| From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy | Q36141302 | ||
| Renal sodium-glucose cotransporter inhibition in the management of type 2 diabetes mellitus | Q36345951 | ||
| SGLT2 Inhibitors and Cardiovascular Risk: Lessons Learned From the EMPA-REG OUTCOME Study | Q36820604 | ||
| Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease | Q36845771 | ||
| Dapagliflozin reduces albuminuria in patients with diabetes and hypertension receiving renin-angiotensin blockers | Q36851156 | ||
| Effects of a new SGLT2 inhibitor, luseogliflozin, on diabetic nephropathy in T2DN rats | Q36852567 | ||
| Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial | Q37400845 | ||
| Altered renal lipid metabolism and renal lipid accumulation in human diabetic nephropathy | Q37603244 | ||
| Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control | Q37679893 | ||
| Biology of human sodium glucose transporters | Q37870037 | ||
| The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia. | Q37940036 | ||
| Effects of diabetes drugs on the skeleton | Q38443008 | ||
| Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes | Q38524435 | ||
| Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. | Q38802437 | ||
| Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes. | Q39954542 | ||
| P921 | main subject | glycobiology | Q899224 |
| P304 | page(s) | 44-48 | |
| P577 | publication date | 2016-11-01 | |
| P1433 | published in | Medicina clínica | Q26854009 |
| P1476 | title | Renal safety profile of sodium-glucose cotransporter-2 inhibitors and other safety data | |
| P478 | volume | 147 Suppl 1 |
Search more.